Bio-Thera Solutions
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-33
RECRUITING3
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO100%
Delay Index: of 5 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +29.0 months). See all sponsors →
Open Bio-Thera Solutions on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Recombinant humanized anti-PD-1 monoclonal antibody injection NCT06123884 |
P2/3 | Recruiting | Cervical Cancer | 526 | 2026-09 (+29 mo) |
| BAT8008 injection NCT06341114 |
P1/2 | Active, not recruiting | Advanced Solid Tumors | 112 | 2026-11-30 (+8 mo) |
| Monoclonal antibody BAT6026 NCT06094179 |
P1/2 | Active, not recruiting | Dermatitis, Atopic | 33 | 2026-12-31 (+23 mo) |
| BAT5906 injection NCT07515079 |
P3 | Recruiting | Diabetic Macular Edema (DME) | 406 | 2027-04-30 |
| BAT4406F Injection NCT06044350 |
P2 | Active, not recruiting | Optic Neuromyelitis Spectrum Disease | 162 | 2027-12-31 (+31 mo) |
| BAT8010 for Injection NCT06376136 |
P1/2 | Active, not recruiting | Advanced Solid Tumors | 218 | 2028-02-29 (+45 mo) |
| BAT4406F NCT07499700 |
P2/3 | Recruiting | Minimal Change Disease (MCD); Focal Segmental Glomerulosclerosis (FSGS) | 192 | 2030-10-26 |